S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
S&P 500   4,269.80 (-0.10%)
DOW   33,859.97 (-0.35%)
QQQ   328.60 (+0.03%)
AAPL   173.78 (-0.44%)
MSFT   290.45 (-0.30%)
META   174.40 (-0.26%)
GOOGL   119.90 (+0.29%)
AMZN   142.04 (-0.04%)
TSLA   910.31 (-0.18%)
NVDA   186.65 (+1.80%)
NIO   19.82 (-1.29%)
BABA   90.38 (+0.68%)
AMD   100.27 (+2.04%)
MU   62.62 (+1.62%)
T   18.40 (-0.11%)
CGC   3.78 (-6.90%)
F   15.98 (-0.31%)
GE   79.03 (-1.11%)
DIS   122.16 (-0.53%)
AMC   20.12 (-5.81%)
PYPL   98.48 (-0.95%)
PFE   48.53 (-1.50%)
NFLX   244.88 (+1.55%)
OTCMKTS:GBIM

GlobeImmune - GBIM Stock Forecast, Price & News

$0.0007
0.00 (0.00%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range
N/A
52-Week Range
$0.00
$0.50
Volume
N/A
Average Volume
55 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GBIM stock logo

About GlobeImmune (OTCMKTS:GBIM) Stock

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.

Receive GBIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeImmune and its competitors with MarketBeat's FREE daily newsletter.

GBIM Stock News Headlines

See More Headlines
Receive GBIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlobeImmune and its competitors with MarketBeat's FREE daily newsletter.

GBIM Company Calendar

Last Earnings
5/12/2016
Today
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GBIM
Previous Symbol
NASDAQ:GBIM
Employees
2
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-211.51

Key Executives

  • Mr. C. Jeffrey Dekker CPA (Age 57)
    Pres, VP of Fin., Treasurer & Sec.
    Comp: $200.05k
  • Dr. Richard C. Duke
    Scientific Founder & Member of Scientific Advisory Board
  • Dr. Donald Bellgrau
    Scientific Founder & Chairman of The Scientific Advisory Board
  • Mr. Thomas A. Keuer (Age 63)
    Acting Head of Manufacturing Operations
  • Dr. Allen L. Cohn M.D. (Age 64)
    Exec. Director Clinical Devel.













GBIM Stock - Frequently Asked Questions

How have GBIM shares performed in 2022?

GlobeImmune's stock was trading at $0.3099 at the beginning of the year. Since then, GBIM stock has decreased by 99.8% and is now trading at $0.0007.
View the best growth stocks for 2022 here
.

How were GlobeImmune's earnings last quarter?

GlobeImmune, Inc. (OTCMKTS:GBIM) issued its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.12. The biopharmaceutical company had revenue of $0.94 million for the quarter.

What other stocks do shareholders of GlobeImmune own?
What is GlobeImmune's stock symbol?

GlobeImmune trades on the OTCMKTS under the ticker symbol "GBIM."

How do I buy shares of GlobeImmune?

Shares of GBIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlobeImmune's stock price today?

One share of GBIM stock can currently be purchased for approximately $0.00.

How can I contact GlobeImmune?

GlobeImmune's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The official website for the company is www.globeimmune.com. The biopharmaceutical company can be reached via phone at (720) 667-2300, via email at susan@sanoonan.com, or via fax at 303-625-2710.

This page (OTCMKTS:GBIM) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.